Create a New Forum Admin Login Member Login Contribute to Voyager Search VoyForums Help Desk VoyForums Exchange VoyForums Directory/Categories VoyForums Homepage VoyForums News FAQ - Frequently Asked Questions

[ Show ]

Support VoyForums

[ Shrink ]

VoyForums Announcement: Programming and providing support for this service has been a labor of love since 1997. We are one of the few services online who values our users' privacy, and have never sold your information. We have even fought hard to defend your privacy in legal cases; however, we've done it with almost no financial support -- paying out of pocket to continue providing the service. Due to the issues imposed on us by advertisers, we also stopped hosting most ads on the forums many years ago. We hope you appreciate our efforts.

Show your support by donating any amount. (Note: We are still technically a for-profit company, so your contribution is not tax-deductible.) PayPal Acct: Feedback:

Donate to VoyForums (PayPal):

Sun, December 22 2024, 15:39:55 PST

[ Login ] [ Main index ] [ Post a new message ] [ Search | Check update time | Archives: 1, 2, 3, 4, 5, 6 ]

Subject: Nonalcoholic steatohepatitis and insulin resistance: interface between gastroenterologists and endocrinologists Author: Scheen AJ, Luyckx FH; Acta Clin Belg. 2003 Mar-Apr;58(2):81-91 [ Next Thread | Previous Thread | Next Message | Previous Message ] Date Posted: Wed, October 08 2003, 8:54:52 PDT In reply to: Heiner Wedemeyer, MD, Michael P. Manns, MD; Medscape Gastroenterology 5(2), 2003 's message, "Fatty Liver Disease -- It's More Than Alcohol and Obesity" on Wed, October 08 2003, 8:33:22 PDT Acta Clin Belg. 2003 Mar-Apr;58(2):81-91. Nonalcoholic steatohepatitis and insulin resistance: interface between gastroenterologists and endocrinologists. Scheen AJ, Luyckx FH. Nonalcoholic steatohepatitis (NASH), along with other forms of nonalcoholic fatty liver disease, is an increasingly common clinico-pathological syndrome. It is frequently associated with obesity, especially visceral fat, and type 2 diabetes, and is intimately related to markers of the insulin resistance syndrome. Both the prevalence and the severity of liver steatosis are related to body mass index, waist circumference, hyperinsulinaemia, hypertriglyceridemia and impaired glucose tolerance. The pathophysiology of NASH involves two steps: 1) insulin resistance, which causes steatosis; 2) and oxidative stress, which produces lipid peroxidation and activates inflammatory cytokines. The identification of subjects who may progress from fatty liver to NASH, and from NASH to fibrosis/cirrhosis is an important clinical challenge as well as the finding of appropriate therapy that could prevent such deleterious process. Substantial weight loss is accompanied by a marked attenuation of insulin resistance and related metabolic syndrome and, concomitantly, by an important regression of liver steatosis in most patients, although mild inflammation may be detected in some subjects. Thus, NASH may be considered as another disease of affluence, as is the insulin resistance syndrome and perhaps being part of it. PMID: 12836490 [PubMed - indexed for MEDLINE] hepatitis c outreach project www.hcop.org [ Next Thread | Previous Thread | Next Message | Previous Message ]

Replies:

Subject Author Date Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study Sorensen HT,et al; J Clin Gastroenterol. 2003 Apr;36(4):356-9 Wed, October 08 2003, 16:15:34 PDT